Can prednisolone (Pediapred) be given to infants with COVID‑19?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can Prednisolone (Pediapred) Be Given to Infants with COVID-19?

Yes, prednisolone can be given to infants with COVID-19, but only in specific clinical scenarios: primarily for Multisystem Inflammatory Syndrome in Children (MIS-C) or severe COVID-19 requiring oxygen support—not for mild or moderate acute COVID-19 infection.

Clinical Context Determines Use

The decision to use prednisolone in infants with COVID-19 depends entirely on the clinical presentation:

When Prednisolone IS Indicated:

MIS-C (Most Common Indication):

  • If the infant meets MIS-C criteria (persistent fever ≥38.5°C, multiorgan involvement, elevated inflammatory markers, and evidence of SARS-CoV-2 exposure), prednisolone is a first-line treatment 1
  • Dosing for MIS-C: Methylprednisolone 1-2 mg/kg/day IV (or equivalent prednisolone dose) alongside IVIG 2 gm/kg 1
  • For refractory MIS-C with persistent fever or significant organ involvement, escalate to methylprednisolone 10-30 mg/kg/day 1

Severe Acute COVID-19:

  • Corticosteroids are recommended for children and adolescents with severe to critical COVID-19 requiring supplemental oxygen or mechanical ventilation 2, 3
  • This applies to infants who develop significant respiratory compromise with hypoxemia

When Prednisolone is NOT Indicated:

Mild to Moderate COVID-19:

  • Corticosteroids are NOT recommended in children and adolescents with mild to moderate COVID-19 who do not require oxygen 2
  • Recent evidence shows no benefit in preventing long COVID in outpatient children treated with steroids during acute infection 4

Practical Dosing Guidance

The FDA label for Pediapred provides flexibility 5:

  • Pediatric dosing range: 0.14 to 2 mg/kg/day in 3-4 divided doses (4-60 mg/m²/day)
  • Specific to clinical severity: Lower doses for less severe conditions; higher initial doses for critical illness
  • Dosing must be individualized based on disease severity and response

For an infant (typically <1 year, weight 5-10 kg):

  • MIS-C: Start with 1-2 mg/kg/day (5-20 mg/day total) divided into doses
  • Severe COVID-19 pneumonia: Similar dosing as MIS-C protocol

Safety Considerations in Infants

Important caveats when using prednisolone in infants:

  • Monitor growth velocity closely - corticosteroids can suppress growth even at low doses and without HPA axis suppression 5
  • Titrate to lowest effective dose to minimize growth effects 5
  • Watch for infections - corticosteroids may suppress immune response to vaccines and increase infection risk 5
  • Avoid abrupt discontinuation - taper gradually after long-term use 5
  • Case reports support safety - prednisolone has been used successfully in infants as young as 2 months for COVID-19-related complications without adverse events 6, 7

Evidence Quality Assessment

The recommendations are based on:

  • Strong guideline evidence from the American College of Rheumatology for MIS-C treatment 1
  • Moderate evidence from international pediatric guidelines supporting corticosteroids only in severe COVID-19 2, 3
  • Emerging evidence suggesting no benefit (and possible harm with high doses) in mild-moderate disease 4, 8

Clinical Algorithm

  1. Assess disease severity:

    • Mild/moderate (no oxygen need) → NO corticosteroids
    • Severe (oxygen requirement) → Consider corticosteroids
    • MIS-C criteria met → Corticosteroids indicated
  2. If corticosteroids indicated:

    • Start methylprednisolone 1-2 mg/kg/day IV or equivalent oral prednisolone
    • Combine with IVIG if MIS-C
    • Monitor inflammatory markers, cardiac function, and clinical response
  3. Escalate if refractory:

    • Persistent fever or worsening organ function → increase to 10-30 mg/kg/day
    • Consider additional immunomodulators (anakinra) 1

Common Pitfalls to Avoid

  • Do not use corticosteroids prophylactically in asymptomatic or mildly symptomatic COVID-19-positive infants
  • Do not use high-dose pulse steroids empirically - associated with increased mortality in ICU patients 8
  • Do not forget eye protection if facial nerve involvement (as in Bell's palsy case) 6
  • Do not stop abruptly - always taper to prevent adrenal insufficiency 5

11556723

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.